JSPR

9.18014.60%
KV

Kurt von Emster

Director

Mr. Kurt von Emster, CFA & CPA, is Managing Partner of Abingworth LLP, which he joined on January 1, 2015. At the firm, he also served as Head of Abingworth Life Sciences, as Joint Managing Partner since July 7, 2015 and as Partner since January 5, 2015. He serves as Director of Entos, Inc. since October 3, 2023, SFJ Pharmaceuticals, Inc. since April 2020, Tizona Therapeutics, Inc. since December 2020, Launch Therapeutics since August 2021, an Independent Director of Iambic Therapeutics, Inc. from September 2023, Orbus Therapeutics, Inc. since July 2020 and as an Independent Director of Jasper Therapeutics, Inc. since November 2019. He is Co-Founder of venBio LLC and also served as Managing Director, Managing Partner and Founding Partner from May 2009 to January 2015. He served as Managing Director from 2001 to 2009, Partner, Portfolio Manager and General Partner at MPM Capital. He served as a Vice President and Portfolio Manager at Franklin Templeton Group, where he was responsible for building the health care group and conceiving and developing a number of different life science investment products. He began his career at Franklin Templeton as a Biotechnology and Healthcare Analyst and Portfolio Manager. Mr. von Emster served as Independent Chairman of the Board at Vera Therapeutics, Inc. until May 24, 2022 and as a Member of the Board of Directors since October 2020. He served as Interim Chairman of Vaxcyte, Inc. from March 2021 to October 2021, as Chairman from July 2015 to July 2017 and as a Director since July 2015. He served as a Non-Independent Director of Cymabay Therapeutics, Inc. from April 2009 until March 22, 2024; as a Director of Attenua, Inc. since April 30, 2018; as an Additional Director of Cytos Biotechnology AG since May 2012; as an Independent Director of CRISPR Therapeutics AG from March 2015 until June 12, 2019; as an Independent Director of Aurinia Pharmaceuticals Inc. from February 14, 2014 to March 6, 2015; as a Director of Pernix Sleep, Inc. since August 2005; as a Director of Somaxon Pharmaceuticals; as a Director of AbbVie Biotherapeutics Inc. since February 24, 2009; as a Member of the Board of Directors of Kesios Therapeutics Limited; as a Director of Facet Biotech Corporation from February 2009 to April 2010; and as a Director of Trishula Therapeutics, Inc. from December 2020 to December 2021. He has several years of experience in life science investment in both private and public companies. Mr. von Emster holds a Bachelor of Science degree in Business and Economics from the University of California at Santa Barbara.

Positions